DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Keppra XR (Levetiracetam) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The prescriber should be aware that the adverse reaction incidence figures in the following table, obtained when KEPPRA XR was added to concurrent AED therapy, cannot be used to predict the frequency of adverse experiences in the course of usual medical practice where patient characteristics and other factors may differ from those prevailing during clinical studies. Similarly, the cited frequencies cannot be directly compared with figures obtained from other clinical investigations involving different treatments, uses, or investigators. An inspection of these frequencies, however, does provide the prescriber with one basis to estimate the relative contribution of drug and non-drug factors to the adverse reaction incidences in the population studied.

KEPPRA XR Tablets

In the well-controlled clinical study using KEPPRA XR in patients with partial onset seizures, the most frequently reported adverse reactions in patients receiving KEPPRA XR in combination with other AEDs, not seen at an equivalent frequency among placebo-treated patients, were irritability and somnolence.

Table 3 lists treatment-emergent adverse reactions that occurred in at least 5% of epilepsy patients treated with KEPPRA XR participating in the placebo-controlled study and were numerically more common than in patients treated with placebo. In this study, either KEPPRA XR or placebo was added to concurrent AED therapy. Adverse reactions were usually mild to moderate in intensity.

Table 3: Incidence (%) Of Treatment-Emergent Adverse Reactions In The Placebo-Controlled, Add-On Study By Body System (Adverse Reactions Occurred In At Least 5% Of KEPPRA XR-Treated Patients And Occurred More Frequently Than Placebo-Treated Patients)
Body System/
Adverse Reaction
KEPPRA XR
(N=77)
%
Placebo
(N=79)
%
Gastrointestinal Disorders   
    Nausea53
Infections and Infestations   
    Influenza84
    Nasopharyngitis75
Nervous System Disorders   
    Somnolence83
    Dizziness53
Psychiatric Disorders   
    Irritability70

Discontinuation Or Dose Reduction In The KEPPRA XR Well-Controlled Clinical Study

In the well-controlled clinical study using KEPPRA XR, 5.2% of patients receiving KEPPRA XR and 2.5% receiving placebo discontinued as a result of an adverse event. The adverse reactions that resulted in discontinuation and that occurred more frequently in KEPPRA XR-treated patients than in placebo-treated patients were asthenia, epilepsy, mouth ulceration, rash and respiratory failure. Each of these adverse reactions led to discontinuation in a KEPPRA XR-treated patient and no placebo-treated patients.

Comparison Of Gender, Age And Race

There are insufficient data for KEPPRA XR to support a statement regarding the distribution of adverse experience reports by gender, age and race.

Table 4 lists the adverse reactions seen in the well-controlled studies of immediate-release KEPPRA tablets in adult patients experiencing partial onset seizures. Although the pattern of adverse reactions in the KEPPRA XR study seems somewhat different from that seen in partial onset seizure well-controlled studies for immediate-release KEPPRA tablets, this is possibly due to the much smaller number of patients in this study compared to the immediate-release tablet studies. The adverse reactions for KEPPRA XR are expected to be similar to those seen with immediate-release KEPPRA tablets.

Immediate-Release KEPPRA Tablets

In well-controlled clinical studies of immediate-release KEPPRA tablets as adjunctive therapy to other AEDs in adults with partial onset seizures, the most frequently reported adverse reactions, not seen at an equivalent frequency among placebo-treated patients, were somnolence, asthenia, infection and dizziness.

Table 4 lists treatment-emergent adverse reactions that occurred in at least 1% of adult epilepsy patients treated with immediate-release KEPPRA tablets participating in placebo-controlled studies and were numerically more common than in patients treated with placebo. In these studies, either immediate-release KEPPRA tablets or placebo was added to concurrent AED therapy. Adverse reactions were usually mild to moderate in intensity.

Table 4: Incidence (%) Of Treatment-Emergent Adverse Reactions In Placebo-Controlled, Add-On Studies In Adults Experiencing Partial Onset Seizures By Body System (Adverse Reactions Occurred In At Least 1% Of Immediate-Release KEPPRA-Treated Patients And Occurred More Frequently Than Placebo-Treated Patients)
Body System/
Adverse Reaction
Immediate-release KEPPRA
(N=769)
%
Placebo
(N=439)
%
Body as a Whole   
    Asthenia159
    Headache1413
    Infection138
    Pain76
Digestive System   
    Anorexia32
Nervous System   
    Somnolence158
    Dizziness94
    Depression42
    Nervousness42
    Ataxia31
    Vertigo31
    Amnesia21
    Anxiety21
    Hostility21
    Paresthesia21
    Emotional Lability20
Respiratory System   
    Pharyngitis64
    Rhinitis43
    Cough Increased21
    Sinusitis21
Special Senses   
    Diplopia21

In addition, the following adverse reactions were seen in other well-controlled studies of immediate-release KEPPRA tablets: balance disorder, disturbance in attention, eczema, hyperkinesia, memory impairment, myalgia, personality disorders, pruritus, and vision blurred.

Postmarketing Experience

In addition to the adverse reactions listed above for immediate-release KEPPRA tablets [see Adverse Reactions ], the following adverse events have been identified during postapproval use of immediate-release KEPPRA tablets. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The listing is alphabetized: abnormal liver function test, hepatic failure, hepatitis, leukopenia, neutropenia, pancreatitis, pancytopenia (with bone marrow suppression identified in some of these cases), thrombocytopenia and weight loss. Alopecia has been reported with immediate-release KEPPRA use; recovery was observed in majority of cases where immediate-release KEPPRA was discontinued.



REPORTS OF SUSPECTED KEPPRA XR SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Keppra XR. The information is not vetted and should not be considered as verified clinical evidence.

Possible Keppra XR side effects / adverse reactions in 36 year old male

Reported by a consumer/non-health professional from United States on 2011-10-13

Patient: 36 year old male

Reactions: Pneumonia, Pulmonary Congestion

Adverse event resulted in: hospitalization

Suspect drug(s):
Keppra XR



Possible Keppra XR side effects / adverse reactions in 32 year old female

Reported by a physician from United States on 2011-10-17

Patient: 32 year old female

Reactions: Thyroid Cancer, Exposure During Breast Feeding, Pregnancy

Suspect drug(s):
Keppra XR

Other drugs received by patient: Folic Acid; Vitamin and Mineral Prenatal Supplement W/ Folic Acid CAP; Synthroid



Possible Keppra XR side effects / adverse reactions in 63 year old male

Reported by a physician from United States on 2011-10-21

Patient: 63 year old male

Reactions: Subdural Haematoma, Head Injury, Mental Status Changes, Fall

Adverse event resulted in: death

Suspect drug(s):
Keppra XR
    Dosage: 500 mg
    Indication: Convulsion

Plavix
    Indication: Coronary Artery Disease

Aspirin
    Indication: Coronary Artery Disease



See index of all Keppra XR side effect reports >>

Drug label data at the top of this Page last updated: 2009-05-21

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017